Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.

Dexmedetomidine for Prophylaxis Against Postoperative Nausea and Vomiting in Highly Susceptible Patients: a Randomised Controlled Comparison of Two Bolus Doses

The study aims to compare between two bolus doses of dexmedetomidine in preventing PONV in highly susceptible patients.

Being A challenging complaint, many studies tried to find an effective preventive strategies for PONV. In this study protocol the investigators aim to compare between 0.5 mic/kg and 0.75 mic/kg bolus doses of dexmedetomidine when given toward the end of head and neck surgeries in highly susceptible patients with a controlled group receiving ondansetron.

The primary outcome is the 1st 24 hours incidence of PONV

Other outcomes include:

• Time to 1st call for rescue antiemetic and the total amount of antiemetics
• Number of PONV attacks
• Post operative pain score with visual analogous scale (VAS) and time to 1st call for rescue analgesia
• Sedation Score using Observer's Assessment of Alertness and sedation (OAA/S)
• Patient satisfaction
• Vital signs in the 1st 24 hours

Inclusion Criteria:

• Two risk factors or more for PONV ( female, non-smoking, postoperative opioids, history of motion sickness or PONV )
• Head and neck surgeries in adults
• ASA ( I , II )

Exclusion Criteria:

• Patients on ( steroids , antiemetics or any drug caude emesis )
• Any active cardiac condition at the time of the surgery
• Pregnancy